Hormonal Contraception and HIV Technical Update
To summarize current evidence and World Health Organization (WHO) revised guidance regarding use of hormonal contraception (HC) by women at high risk of acquiring HIV. On March 2, 2017, WHO issues revised guidance on the use of progestogen-only injectables (norethisterone enanthate [NET-EN] and depot medroxyprogesterone acetate [DMPA], in both intramuscular [IM] and subcutaneous [SC] forms) by women at high risk of HIV acquisition.
File:
Year:
2017
Organization:
USAID
PEPFAR
Center for Disease Control and Prevention
Languages:
English